This site is intended for healthcare professionals
MS: learnings from the pandemic and innovations in patient care

Improving established MS therapies

Read time: 60 mins
Last updated:9th Jul 2021
Published:9th Jul 2021

How can long-term understanding of established therapies for multiple sclerosis (MS) be harnessed to improve the patient experience? Watch clips from this virtual satellite symposium to:

  • Learn about the tolerability and possibilities with intramuscular administration of peginterferon beta-1a
  • Discover new research showing how a different fumarate chemical structure can affect gastrointestinal (GI) tolerability and work productivity while maintaining bioequivalent levels of the circulating active compound mycophenolate mofetil (MMF)
  • Explore how subcutaneous (SC) administration of natalizumab can reduce the burden of treatment for patients and the healthcare system, a topic of particular relevance during the pandemic
  • Keep up to date with how long-term safety data is changing the use of established MS therapies
  • Consider new data and guidelines for MS therapies as they relate to COVID-19

In this virtual satellite symposium, Professors Til Menge, Anne-Katrin Pröbstel and Bart Van Wijmeersch discuss the latest updates to MS treatments, with a focus on individualising MS care to achieve clinically meaningful outcomes and improve patient experiences. These presentations will present data illustrating that:

  • Intramuscular administration of peginterferon beta-1a provides an option for reduced injection-site reactions in the interferon format that is the least frequently administered
  • Diroximel fumarate* results in fewer GI side effects that impact quality of life than observed with dimethyl fumarate
  • Subcutaneous administration of natalizumab is a high efficacy treatment option with improved convenience and flexibility vs intravenous administration

You can help us improve the content we produce for you and your colleagues by taking this short survey. It´s only 5 questions and shouldn´t take more than 1-2 minutes of your time, but it would help us tremendously. Survey produced by Biogen. Responses are anonymous and no personal data will be transferred.

Take Biogen’s short survey

How can long-term experiences with MS therapies facilitate advancements to further individualise MS care?

What are the possibilities with intramuscular administration of peginterferon beta-1a?

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Can a next-generation fumarate advance clinically meaningful outcomes for MS patients? 

In the following four videos, Assistant Professor Anne-Katrin Pröbstel explores the similarities and differences between dimethyl fumarate (DMF) and diroximel fumarate (DRF). 

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Can a subcutaneous (SC) route of administration of natalizumab enhance flexibility and convenience for patients?

In the three videos below, Professor Bart Van Wijmeersch discusses milestones in the 15 years of clinical experience with intravenous natalizumab, recently published data on natalizumab SC and the implications for its availability to patients and clinics.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

What other aspects should be considered regarding the advancements to peginterferon beta-1a, fumarate* and natalizumab options? 

In the nine videos below, the expert faculty ask each other to highlight the latest data or guidance that would help them better address the types of decisions they need to make for the individual situations of their different patients.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Now you’ve watched the highlights of the ‘Advancing MS Therapy: Addressing the Patient Experience’ symposium, why not test your knowledge on intramuscular peginterferon beta-1a, diroximel fumarate, and subcutaneous natalizumab.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: